PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20540652-0	2010	Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.	Pioglitazone	58-70	erythropoietin	Homo sapiens	85-99	
20540652-1	2010	BACKGROUND: We aimed to assess the effect of long-term pioglitazone treatment on erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.	Pioglitazone	55-67	erythropoietin	Homo sapiens	81-95	
20540652-4	2010	RESULTS: Pioglitazone effectively reduced erythropoietin dose and maintained the target hemoglobin levels by improving insulin resistance up to the end of the study.	Pioglitazone	9-21	erythropoietin	Homo sapiens	42-56	
20540652-9	2010	Erythropoietin responsiveness improved with a reduction in erythropoietin dose and may be associated with the improvement in insulin resistance due to long-term pioglitazone treatment.	Pioglitazone	161-173	erythropoietin	Homo sapiens	0-14